Novita believes that an increasing number of innovative new drugs and medical devices will be initially developed at small, nimble companies that source innovative ideas from the laboratories of industry and academia, develop products through pre-clinical or early clinical proof of concept stages, and then hand off later stage development and commercialization to companies with a global reach.

Novita is well positioned to run the early leg of this development race.

We value relationships with key individuals at companies interested in acquiring late preclinical or early clinical stage biopharmaceuticals and medical devices - especially in the cardiovascular, renal, and gastrointestinal fields.

>> Contact us to inquire about products that Novita is currently developing that may be available for out-licensing, partnering or acquisition